News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Female Health Company's Distributor, Sekunjalo Investments Corporation (Pty) Ltd., Awarded Contract for up to 11 Million FC2 Female Condoms in the Republic of South Africa


9/19/2011 11:11:23 AM

CHICAGO, Sep. 19, 2011 /PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO) today announced that its exclusive distributor in the Republic of South Africa (RSA), Sekunjalo Investments Corporation (PTY) Ltd., was awarded a contract to supply the Ministry of Health (MOH) up to 11 million FC2 Female Condoms. The contract is valid through August 31, 2012. The tender quantity of 11 million units is a significant increase from the RSA's last tender (4 million units), evidencing the country's growing demand for female condoms. Units supplied during the contract term can be increased over the specified quantity at the purchasers' request.

O.B. Parrish, Chairman and C.E.O. of The Female Health Company, noted that "the Company is delighted at RSA's decision to continue to supply our high-quality, effective product that provides women with options to control their sexual health, particularly HIV/AIDS prevention".

The FC2 Female Condom has been approved by the FDA as a Class III medical device and has been cleared by the World Health Organization for purchase by U. N. Agencies.

About The Female Health Company

The Female Health Company (FHC), based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and about 100 other countries around the world. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in the U.S., Europe, Canada, Australia, South Africa, Japan, China, Spain, Mexico, Greece and Turkey and are pending in various countries. The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.

About Sekunjalo Investments Corporation (PTY) Ltd.

Sekunjalo Investments Corporation Pty Ltd was established fourteen years ago for the express purpose of supplying the South African National Dept. of Health with male condoms on government tender. Sekunjalo has been FHC's chosen partner in the Republic of South Africa for seven years, successfully supplying Female Condoms to hundreds of government clinics across the provinces on tender. The Sekunjalo partnership also owns and operates Barrs Pharmaceuticals, a GMP-approved pharmaceutical factory located in Cape Town, from which it supplies many medicinal products to governments in Southern Africa, also through tender processes.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical fact are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release relate to the timing and size of shipments under the RSA's contract. These statements are based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward-looking statements are inherently subject to known and unknown risks and uncertainties. The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward-looking statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity, efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the fiscal year ended September 30, 2010. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com.

SOURCE The Female Health Company


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES